Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward B Garon

Showing results (81-90 of 204) with videos related to

Pageof 21
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 23, 2020
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLCXiuning Le, Monique Nilsson, Jonathan Goldman, et al.
Molecular Cancer Therapeutics|July 1, 2010
Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell linesEdward B Garon, Richard S Finn, Wylie Hosmer, et al.
Clinical Lung Cancer|November 30, 2016
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung CancerEdward B Garon, Martin Reck, Luis Paz-Ares, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2018
A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic TreatmentTimothy J Williamson, Alyssa K Choi, Julie C Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancerZorawar S Noor, Jonathan W Goldman, William E Lawler, et al.
Molecular Cancer Therapeutics|November 19, 2024
Characteristics of a CCL21 Gene-Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non-Small Cell Lung CancerMichael S Oh, Camelia Dumitras, Ramin Salehi-Rad, et al.
Molecular Cancer Research : MCR|January 29, 2014
PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLCKostyantyn Krysan, Rebecca Kusko, Tristan Grogan, et al.
Clinical Lung Cancer|January 11, 2018
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib ResultsMartin Reck, Edward B Garon, Luis Paz-Ares, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2022
cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and EvolutionShuo Li, Weihua Zeng, Xiaohui Ni, et al.
Drug Safety|December 20, 2021
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and ManageabilityErnest Nadal, Hidehito Horinouchi, Jin-Yuan Shih, et al.
Pageof 21

Showing results (81-90 of 204) with videos related to

Sort By:
Pageof 21
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 23, 2020
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLCXiuning Le, Monique Nilsson, Jonathan Goldman, et al.
Molecular Cancer Therapeutics|July 1, 2010
Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell linesEdward B Garon, Richard S Finn, Wylie Hosmer, et al.
Clinical Lung Cancer|November 30, 2016
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung CancerEdward B Garon, Martin Reck, Luis Paz-Ares, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2018
A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic TreatmentTimothy J Williamson, Alyssa K Choi, Julie C Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancerZorawar S Noor, Jonathan W Goldman, William E Lawler, et al.
Molecular Cancer Therapeutics|November 19, 2024
Characteristics of a CCL21 Gene-Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non-Small Cell Lung CancerMichael S Oh, Camelia Dumitras, Ramin Salehi-Rad, et al.
Molecular Cancer Research : MCR|January 29, 2014
PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLCKostyantyn Krysan, Rebecca Kusko, Tristan Grogan, et al.
Clinical Lung Cancer|January 11, 2018
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib ResultsMartin Reck, Edward B Garon, Luis Paz-Ares, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2022
cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and EvolutionShuo Li, Weihua Zeng, Xiaohui Ni, et al.
Drug Safety|December 20, 2021
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and ManageabilityErnest Nadal, Hidehito Horinouchi, Jin-Yuan Shih, et al.
Pageof 21